Simplex Trading’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-148,300
| Closed | -$3.57M | – | 10422 |
|
|
2023
Q1 | $3.57M | Buy |
148,300
+117,600
| +383% | +$1.48M | ﹤0.01% | 1505 |
|
|
2022
Q4 | $324K | Buy |
30,700
+18,100
| +144% | +$146K | ﹤0.01% | 3648 |
|
|
2022
Q3 | $56K | Buy |
12,600
+6,300
| +100% | +$28.7K | ﹤0.01% | 6298 |
|
|
2022
Q2 | $25K | Sell |
6,300
-8,400
| -57% | -$39.8K | ﹤0.01% | 7370 |
|
|
2022
Q1 | $107K | Buy |
14,700
+8,400
| +133% | +$50.2K | ﹤0.01% | 6045 |
|
|
2021
Q4 | $35K | Sell |
6,300
-36,800
| -85% | -$234K | ﹤0.01% | 7719 |
|
|
2021
Q3 | $359K | Buy |
43,100
+17,700
| +70% | +$114K | ﹤0.01% | 4625 |
|
|
2021
Q2 | $214K | Buy |
25,400
+25,255
| +17,417% | +$204K | ﹤0.01% | 5575 |
|
|
2021
Q1 | $152K | Buy |
145
+108
| +292% | +$1.52K | ﹤0.01% | 5169 |
|
|
2020
Q4 | $62K | Sell |
37
-175
| -83% | -$2.62K | ﹤0.01% | 5961 |
|
|
2020
Q3 | $271K | Sell |
212
-169
| -44% | -$2.13K | ﹤0.01% | 3725 |
|
|
2020
Q2 | $537K | Buy |
381
+159
| +72% | +$2.01K | ﹤0.01% | 2807 |
|
|
2020
Q1 | $204K | Buy |
222
+64
| +41% | +$825 | ﹤0.01% | 3572 |
|
|
2019
Q4 | $235K | Buy |
158
+35
| +28% | +$312 | ﹤0.01% | 3579 |
|
|
2019
Q3 | $83K | Buy |
+123
| New | +$1.24K | ﹤0.01% | 4517 |
|
Other funds holding PRVB
Simplex Trading's PRVB Position: Q2 2023 in Review
Simplex Trading sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 47,345 shares — an estimated $1.14M sold.
Simplex Trading first reported a position in PRVB in Q3 2019 and held it in 14 quarters. The position peaked at $1.14M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Simplex Trading reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Simplex Trading sold 47,345 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $1.14M.
- Simplex Trading first reported a position in Provention Bio, Inc. Common Stock in Q3 2019 and held it in 14 quarters.
- Simplex Trading's Provention Bio, Inc. Common Stock position peaked at $1.14M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Simplex Trading's 13F filing for Q2 2023, filed 4 Aug 2023.